CPIX has 36-month beta value of -0.18. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CPIX is 7.84M, and currently, short sellers hold a 6.39% ratio of that float. The average trading volume of CPIX on March 04, 2025 was 3.38M shares.
CPIX) stock’s latest price update
Cumberland Pharmaceuticals Inc (NASDAQ: CPIX)’s stock price has gone rise by 5.76 in comparison to its previous close of 4.86, however, the company has experienced a 1.98% increase in its stock price over the last five trading days. prnewswire.com reported 2025-02-25 that NASHVILLE, Tenn., Feb. 25, 2025 /PRNewswire/ — Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its annual 2024 financial results and provide a company update after the market closes on Tuesday, March 4, 2025.
CPIX’s Market Performance
Cumberland Pharmaceuticals Inc (CPIX) has seen a 1.98% rise in stock performance for the week, with a 128.44% gain in the past month and a 363.06% surge in the past quarter. The volatility ratio for the week is 10.79%, and the volatility levels for the past 30 days are at 19.90% for CPIX. The simple moving average for the past 20 days is 5.73% for CPIX’s stock, with a 172.91% simple moving average for the past 200 days.
Analysts’ Opinion of CPIX
Many brokerage firms have already submitted their reports for CPIX stocks, with UBS repeating the rating for CPIX by listing it as a “Neutral.” The predicted price for CPIX in the upcoming period, according to UBS is $5 based on the research report published on November 12, 2012 of the previous year 2012.
UBS, on the other hand, stated in their research note that they expect to see CPIX reach a price target of $6.50, previously predicting the price at $8. The rating they have provided for CPIX stocks is “Neutral” according to the report published on February 01st, 2011.
UBS gave a rating of “Neutral” to CPIX, setting the target price at $8 in the report published on December 16th of the previous year.
CPIX Trading at 52.16% from the 50-Day Moving Average
After a stumble in the market that brought CPIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.51% of loss for the given period.
Volatility was left at 19.90%, however, over the last 30 days, the volatility rate increased by 10.79%, as shares surge +127.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +142.45% upper at present.
During the last 5 trading sessions, CPIX rose by +1.98%, which changed the moving average for the period of 200-days by +233.77% in comparison to the 20-day moving average, which settled at $4.86. In addition, Cumberland Pharmaceuticals Inc saw 116.88% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CPIX
Current profitability levels for the company are sitting at:
- -0.19 for the present operating margin
- 0.74 for the gross margin
The net margin for Cumberland Pharmaceuticals Inc stands at -0.3. The total capital return value is set at -0.16. Equity return is now at value -35.76, with -13.21 for asset returns.
Based on Cumberland Pharmaceuticals Inc (CPIX), the company’s capital structure generated 0.46 points at debt to capital in total, while cash flow to debt ratio is standing at -0.07. The debt to equity ratio resting at 0.87. The interest coverage ratio of the stock is -12.69.
Currently, EBITDA for the company is 0.15 million with net debt to EBITDA at -1.03. When we switch over and look at the enterprise to sales, we see a ratio of 2.07. The receivables turnover for the company is 3.25for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.13.
Conclusion
To put it simply, Cumberland Pharmaceuticals Inc (CPIX) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
